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Why Do We Need the Flu Shot Every Year?
There is a need for a new vaccine every year due to 
antigenic drift. The antibodies that your body produced 
in response to last year’s flu shot are specific to the viral 
antigens from that year’s version of the vaccine. When 
a mutated version of that virus enters the body, these 
antibodies are no longer able to evoke an immune re-
sponse (Potter, 2008). Since the virus mutates slightly 
each season, new vaccines with slightly different an-
tigen combinations must be developed to recognize 
the hemagglutinin and neuraminidase proteins of the 
mutated virus.  Once the vaccine is administered, your 
innate immune system will create a cascade effect to 
activate B-cells to produce antibodies. If you were to 
contract the influenza virus, ideally your body would al-
ready have the necessary antibodies to fight the virus 
and produce minimal flu-like symptoms. The vaccine 
enables our bodies to combat the virus by generating 
antibodies in advance. Within two weeks of vaccination, 
the adaptive immune system should have generated 
appropriate defenses against contracting the seasonal 
strain of the flu (CDC). 
How Do I Choose a Vaccine?
The two most conventional types of flu vaccinations are 
egg based. These include the killed vaccine, taken as 
an intramuscular shot or live attenuated nasal spray 
vaccine (CDC). The killed vaccine involves injecting 
a fertilized hen egg with the influenza virus and later 
harvesting and purifying the viral fluid to acquire the in-
activated viral antigen. The live attenuated vaccination 
is a weakened version of four common strains of live 
influenza viruses. This attenuated nasal spray is not 
recommended for people over 50 or immunodeficient 
recipients. Live attenuated vaccine is cold adapted, so 
the virus cannot survive and replicate in the warm envi-
ronment of the lungs and cause an infection. Although 
vaccines are developed using viruses, the flu shot can-
not cause the flu.
Innovations within the past five years include cell-based 
and recombinant technology (Nation Vaccine Informa-
tion Center). The inactivated cell-based flu shot is pro-
duced in a similar way to the egg-based killed vaccine, 
but the viral antigen is extracted from a mammalian cell 
culture rather than utilizing chicken eggs. The recombi-
nant vaccine requires isolating a gene expressing viral 
specific protein. Typically the gene encoding for HA is 
injected into an insect virus, so it can be replicated with-
in insect cells. This process is faster than other meth-
ods because the virus does not need to undergo an at-
tenuation phase to grow in eggs or cell cultures (CDC). 
Recent Trials for Vaccine Development
Since the first influenza outbreak 100 years ago, a uni-
versal flu vaccine may become available in the near fu-
ture. BiondVax’s M-001 peptide vaccine has reached a 
phase 3 clinical trial in Europe. Instead of targeting the 
seasonally variable antigen surface of hemagglutinin 
and neuraminidase proteins, M-001 targets nine high-
ly conserved epitopes of the flu virus. These epitopes, 
which are part of an antigen that are recognized by the 
immune system, don’t change seasonally. So, ideally, 
you would only need one universal flu shot that would 
be effective for your lifetime. This approach allows for 
protection against all strains of influenza virus. Getting 
the universal vaccine in conjunction with the seasonal 
vaccine stimulates antibody production against hem-
agglutinin and has the most promising immunological 
success rate according to data acquired so far from the 
clinical trials (Taylor, 2018). About a dozen more influ-
enza universal vaccines, each founded upon slightly 
modified approaches, are in the earlier stages of clin-
ical trials. Increased public cooperation coupled with 
advancements in biomedical vaccination technology 
will hopefully lead to the stark decrease and eventual 
eradication of influenza viruses. 
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To this day, smallpox is the only disease confirmed to be 
eradicated worldwide. This would not have been possi-
ble without the first widely utilized vaccine developed 
nearly 200 years prior by Edward Jenner. Inspired by 
Jenner’s methodology of using the cowpox virus to pro-
tect against smallpox in humans, vaccine innovations 
and their significance to public health took off after Lou-
is Pasteur’s discovery of the rabies vaccine in 1885. 
Vaccines are perhaps the greatest immunological feat 
to this day. So why are people still so averse to getting 
vaccinated, especially for the flu? Encouraging people 
to get their annual flu shot and persuading the public of 
its effectiveness are two vital measures for preventing 
flu-related hospitalizations and deaths.
Flu History 
World War I played a significant role in the first influ-
enza outbreak. The war brought the mass mobilization 
of over 60 million soldiers with significantly different 
backgrounds and immune systems to highly concen-
trated war zones in Europe. This, coupled with years 
of unsanitary lifestyles, facilitated high transmission 
rates leading to the H1N1 influenza pandemic outbreak 
in 1918 (Matthews, 2014). Over 50 million people died 
and many more were infected by the end of this pan-
demic. At the time, the only preventative measure that 
was exercised was quarantine. 
About twenty years later, the influenza A and B viruses 
were isolated in the lab. Although vaccinations against 
this virus have been in development since the 1930’s, 
numerous clinical trials have debunked the effective-
ness of the influenza vaccine for decades after the 
1918 pandemic (National Vaccine Information Center). 
A century after the first influenza outbreak, the CDC re-
ported that the flu vaccine decreases the prevalence of 
flu related illness, hospitalization, and death, especially 
in young children and elderly people. Numerous stud-
ies have suggested that the trivalent influenza vaccine 
significantly reduces flu-related hospitalizations and fa-
talities (Nichols, 2018). The effectiveness of the flu vac-
cine varies from year to year depending on how well the 
projected vaccine antigen sequences matches the ac-
tual seasonal viral antigen. Although some years have 
better predictions than others, the overall effectiveness 
of the vaccine tends to be 40-60% (CDC). 
What is the Flu Virus?
The influenza virus is characterized by two envelope 
proteins. Hemagglutinin (HA) is the protein that allows 
the virus to attach to host cells, while neuraminidases 
(NA) release the virus from the host cell (Morgridge). 
There are sixteen known types of hemagglutinin and 
nine known types of neuraminidase, which gives 144 
different possible combinations of these proteins (Mor-
gridge). Different viral strains contain distinct hemag-
glutinin and neuraminidase proteins, such as H1N1, 
the most common influenza A known as the “swine flu.” 
Influenza vaccines contain three to four of the most 
common influenza strains, which are typically H1N1, 
H2N2, H2N3, and influenza B. The flu vaccine tends to 
be twice as effective in preventing H1N1 than H2N3 and 
influenza B (Rondy et al., 2018). This is one reason why 
the vaccine is not effective for everyone.
Waves of first influenza outbreak 1918 (Potter, 2008)
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